-
3 days ago | 
ascopost.com | Caroline Helwick |Chase Doyle
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers and clinicians.
-
1 month ago | 
ascopost.com | Chase Doyle
Postmastectomy radiation therapy may be significantly shortened for many patients planning breast reconstruction, according to data from a large phase III trial (RT CHARM, Alliance A221505).1 Investigators reported that hypofractionated (short-course) radiation therapy was found to be noninferior to conventional fractionation in patients with breast cancer who underwent breast reconstruction after mastectomy.
-
1 month ago | 
ascopost.com | Chase Doyle
Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PARTIQoL trial. This phase III trial showed no measurable differences between the two approaches in terms of bowel function, urinary symptoms, or sexual function.
-
1 month ago | 
ascopost.com | Chase Doyle
Current standard chemoradiation therapy remains the most effective treatment for selected patients with human papillomavirus (HPV)-positive oropharyngeal cancer, based on the results of the NRG-HN005 trial. Researchers have halted this large, randomized phase II/III trial after patients in the control arm reached an unprecedented 2-year progression-free survival rate of 98%, setting a new benchmark for treatment efficacy in early-stage, HPV-associated oropharyngeal cancer.
-
1 month ago | 
ascopost.com | Chase Doyle
Neoadjuvant therapy that combines chemotherapy, radiotherapy, and the investigational PD-1 inhibitor sintilimab led to a significantly higher pathologic complete response rate in patients with locally advanced esophageal squamous cell carcinoma, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.1 Preliminary results from the multicenter phase III SCIENCE trial conducted in China revealed that neoadjuvant chemoradiotherapy combined with sintilimab achieved a...
-
1 month ago | 
ascopost.com | Chase Doyle
The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Primary results of the phase III inMIND trial demonstrated a median progression-free survival of 22.4 months with tafasitamab vs 13.9 months in the placebo arm,...
-
1 month ago | 
specialtypharmacycontinuum.com | Chase Doyle |Sarah Tilyou
Originally published by our sister publication Gastroenterology & Endoscopy NewsBy Chase Doyle and Sarah TilyouDENVER—Despite two decades of progress in ablation techniques, the incidence of esophageal cancer has remained largely unchanged, prompting some experts to reevaluate their approach to management of Barrett’s esophagus. In a presentation at the 2024 annual meeting of the American Foregut Society.
-
1 month ago | 
ascopost.com | Chase Doyle
The 2025 ASCO Gastrointestinal Cancers Symposium once again delivered a slate of high-impact studies spanning esophageal, gastric, hepatocellular, pancreatic, biliary tract, and colorectal malignancies. Experts in the field offered fresh perspectives on evolving standards of care, and investigators shared cutting-edge results that promise to shape future treatment strategies.
-
2 months ago | 
ascopost.com | Chase Doyle
Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual disease (MRD) after induction therapy, according to data presented during the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition.1 Initial results of the ECOG-ACRIN EA4151 trial showed that ASCT provided no significant benefit in overall survival or progression-free survival...
-
2 months ago | 
ascopost.com | Chase Doyle
In previously untreated patients with locally advanced or metastatic urothelial carcinoma, use of the antibody-drug conjugate enfortumab vedotin-ejfv in combination with the PD-1 inhibitor pembrolizumab continues to demonstrate a significant survival benefit over chemotherapy, according to updated data presented at the 2025 ASCO Genitourinary Cancers Symposium.1 Additional follow-up data from the phase III EV-302 trial, which evaluated enfortumab vedotin plus pembrolizumab as a first-line...
